<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Radiofrequency Ablation" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/radiofrequency-ablation/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/radiofrequency-ablation/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2009-02-28T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Radiofrequency Ablation" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-07T07:15:32+00:00","datePublished":"2009-02-28T17:00:00+00:00","description":"Rationale and Objectives","headline":"Radiofrequency Ablation","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/radiofrequency-ablation/"},"url":"https://clinicaltree.github.io/posts/radiofrequency-ablation/"}</script><title>Radiofrequency Ablation | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Radiofrequency Ablation</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Radiofrequency Ablation</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1235840400" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Feb 28, 2009 </em> </span> <span> Updated <em class="" data-ts="1680851732" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 7, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Hanping Wu MD PhD</a> </em>, <em> <a href="">Agata A. Exner PhD</a> </em>, <em> <a href="">Tianyi M. Krupka BS</a> </em>, <em> <a href="">Brent D. Weinberg PhD</a> </em>, <em> <a href="">Ravi Patel BS</a> </em>, <em> <a href="">John R. Haaga MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2263 words"> <em>12 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Inflammatory reaction surrounding the ablated area is a major confounding factor in the early detection of viable tumor after radiofrequency (RF) ablation. A difference in the responsiveness of normal and tumor blood vessels to vasoactive agents may be used to distinguish these regions in post-ablation follow-up. The goal of this study was to examine longitudinal perfusion changes in untreated viable tumor and the peripheral hyperemic rim of RF-ablated tumor in response to a vasoconstrictor (phenylephrine) or vasodilator (hydralazine) in a subcutaneous rat tumor model.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Bilateral subcutaneous shoulder tumors were inoculated in 24 BDIX rats and evenly divided into two groups (phenylephrine and hydralazine groups). One tumor in each animal was completely treated with RF ablation (at 90 ± 2°C for 3 minutes), and the other remained untreated. Computed tomographic perfusion scans before and after phenylephrine (10 μg/kg) or hydralazine (5 mg/kg) administration were performed 2, 7, and 14 days after ablation. Four rats per group were euthanized on each scan day, and pathologic evaluation was performed. The changes of blood flow in the peripheral rim of ablated tumor and untreated viable tumor in response to phenylephrine or hydralazine at each time point were compared. The diagnostic accuracy of viable tumor using the percentage change of blood flow in response to phenylephrine and hydralazine was compared using receiver-operating characteristic analysis.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The peripheral rim of ablated tumor presented with a hyperemic reaction with dilated vessels and congestion on day 2 after ablation, numerous inflammatory vessels on day 7, and granulation tissue formation on day 14. Phenylephrine significantly decreased the blood flow in the peripheral hyperemic rim of ablated tumor on days 2, 7, and 14 by 16.3 ± 9.7% ( <em>P</em> = .001), 24.0 ± 22.6% ( <em>P</em> = .007), and 31.1 ± 25.4% ( <em>P</em> = .045), respectively. In untreated viable tumor, the change in blood flow after phenylephrine was irregular and insignificant. Hydralazine decreased the blood flow in the peripheral rim of both ablated tumor and untreated viable tumor. Receiver-operating characteristic analysis showed that reliable tumor diagnosis using the percentage change of blood flow in response to phenylephrine was noted on days 2 and 7, for which the areas under the curve were 0.82 (95% confidence interval, 0.64–1.00) and 0.81 (95% confidence interval, 0.56–1.00), respectively. However, tumor diagnosis using the blood flow change in response to hydralazine was unreliable.</p><h2 id="conclusion"><span class="mr-2">Conclusion</span><a href="#conclusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Phenylephrine markedly decreased blood flow in the peripheral hyperemic rim of ablated tumor but had little effect on the untreated viable tumor. Computed tomographic perfusion with phenylephrine may be useful in the long-term treatment assessment of RF ablation.</p><p>Interventional oncologic procedures such as chemical ablation, laser ablation, radiofrequency (RF) ablation, and microwave ablation have been widely used in unresectable solid tumor treatment. These techniques can provide efficacious, cost-effective management of localized cancer sites . However, local recurrence due to factors such as large tumor size (&gt;3 cm), irregular contours, and affluent blood supply continues to be a main cause of treatment failure . The early detection of residual or locally recurrent tumor after interventional treatment is critical and can facilitate successful retreatment at an early stage.</p><p>Contrast-enhanced computed tomography and magnetic resonance (MR) are currently used to evaluate RF ablation efficacy. However, an inflammatory peripheral rim induced by ablation, which presents as enhancement surrounding the coagulated zone, can obscure viable residual tumor. The histologic examination of ablated tumors has shown that the sensitivity of computed tomography or MR for the detection of viable tumor after ablation ranges from 36% to 86% . Recent reports that positron emission tomography/computed tomography can increase the sensitivity and accuracy for the detection of residual tumor are promising , but this modality may not be sufficiently cost effective to become a routine follow-up method. New imaging methods are needed for the successful and accurate follow-up of local tumor ablation therapy.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="overall-experimental-design"><span class="mr-2">Overall Experimental Design</span><a href="#overall-experimental-design" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="animal-model"><span class="mr-2">Animal Model</span><a href="#animal-model" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="rf-ablation"><span class="mr-2">RF Ablation</span><a href="#rf-ablation" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="ct-perfusion"><span class="mr-2">CT Perfusion</span><a href="#ct-perfusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-analysis"><span class="mr-2">Image Analysis</span><a href="#image-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="histopathologic-examination"><span class="mr-2">Histopathologic Examination</span><a href="#histopathologic-examination" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="ct-perfusion-findings-and-corresponding-histologic-correlation"><span class="mr-2">CT Perfusion Findings and Corresponding Histologic Correlation</span><a href="#ct-perfusion-findings-and-corresponding-histologic-correlation" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/0_1s20S1076633208005394.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/0_1s20S1076633208005394.jpg" alt="Figure 1, Correlation of perfusion images ( [a] maximum-intensity projection, [b] blood flow) with histology ( [c] 4×, [d] 200× [hematoxylin and eosin]) in an untreated tumor. The central zone ( asterisks ) of the tumor presents hyperdense on the maximum-intensity projection image (a) , shows no perfusion (b) , and appears necrotic on the corresponding histologic image (c) . The tumor rim consists of densely packed viable tumor cells encased by a hypervascular fibrous capsule (d) ." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/1_1s20S1076633208005394.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/1_1s20S1076633208005394.jpg" alt="Figure 2, Representative hematoxylin and eosin histology ( [a,c,e] 4×, [b,d,f] 200×) of tumor progression after radiofrequency ablation on days 2 (a,b) , 7 (c,d) , and 14 (e,f) . (a) On day 2, coagulative necrosis was seen in the ablation zone. In the peripheral rim (b) (white square) , a hyperemic reaction zone with dilated vessels and red blood cell infiltration is present. (c) On day 7, numerous blood vessels were found in the peripheral rim of the ablation zone (d) (white square) . The lumen of these vessels shrank to normal. (e) On day 14, granulation tissue formed in the margin of the ablation zone (f) (white square) , and the quantity of blood vessels decreased." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/2_1s20S1076633208005394.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/2_1s20S1076633208005394.jpg" alt="Figure 3, Blood flow in the peripheral rim of ablated tumor (solid line) and untreated viable tumor (dashed line) . Error bar represents the standard error of the mean. ∗ P &lt; .01 versus untreated tumor (Student's unpaired t test)." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="blood-flow-changes-in-the-peripheral-rim-of-ablated-tumor-and-untreated-viable-tumor-in-response-to-phenylephrine"><span class="mr-2">Blood Flow Changes in the Peripheral Rim of Ablated Tumor and Untreated Viable Tumor in Response to Phenylephrine</span><a href="#blood-flow-changes-in-the-peripheral-rim-of-ablated-tumor-and-untreated-viable-tumor-in-response-to-phenylephrine" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Changes in Blood Flow (mL/100 mL/min) in the Peripheral Rim of Ablated Tumor, Untreated Viable Tumor, and Muscle in Response to Phenylephrine</p><p>Peripheral Rim of Ablated Tumor Untreated Viable Tumor Muscle Day_n_ Pre Post % Change Pre Post % Change Pre Post % Change 2 12 52.8 ± 19.5 44.1 ± 18.2 ∗ −16.3 ± 9.7 46.9 ± 12.9 52.2 ± 24.0 11.0 ± 32.7 4.7 ± 3.3 2.9 ± 2.3 −36.8 ± 54.7 7 8 69.2 ± 26.3 52.2 ± 25.1 ∗ −24.0 ± 22.6 51.4 ± 8.2 49.0 ± 8.4 −4.5 ± 9.0 4.8 ± 4.7 3.7 ± 3.7 −1.6 ± 56.8 14 4 73.5 ± 14.5 49.5 ± 17.3 † −31.1 ± 25.4 46.9 ± 10.0 46.5 ± 16.9 1.8 ± 35.0 5.1 ± 5.3 2.1 ± 1.9 −61.2 ± 17.8</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/3_1s20S1076633208005394.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/3_1s20S1076633208005394.jpg" alt="Figure 4, Plots of percentage change of blood flow in untreated viable tumor (a) and peripheral rim of ablated tumor (b) induced by phenylephrine to baseline blood flow of 24 tested tumors. SD, standard deviation." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/4_1s20S1076633208005394.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/4_1s20S1076633208005394.jpg" alt="Figure 5, Maximum-intensity projection (MIP) and blood flow images before and after phenylephrine injection on days 2, 7, and 14 show that phenylephrine had little effect on blood flow in untreated tumor (left) and decreased flow in the peripheral rim of ablated tumor (right) . Dotted lines mark the region of untreated viable tumor (left) and the peripheral rim of ablated tumor (right) . L, left; RF, radiofrequency." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="perfusion-changes-in-the-peripheral-rim-of-ablated-tumor-and-untreated-viable-tumor-in-response-to-hydralazine"><span class="mr-2">Perfusion Changes in the Peripheral Rim of Ablated Tumor and Untreated Viable Tumor in Response to Hydralazine</span><a href="#perfusion-changes-in-the-peripheral-rim-of-ablated-tumor-and-untreated-viable-tumor-in-response-to-hydralazine" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 2</p><p>Changes in Blood Flow (mL/100 mL/min) in the Peripheral Rim of Ablated Tumor, Untreated Viable Tumor, and Muscle in Response to Hydralazine</p><p>Peripheral Rim of Ablated Tumor Untreated Viable Tumor Muscle Day_n_ Pre Post % Change Pre Post % Change Pre Post % Change 2 12 47.2 ± 20.1 38.1 ± 12.8 ∗ −15.0 ± 25.9 40.9 ± 11.1 28.8 ± 9.1 † −27.5 ± 19.1 5.6 ± 2.3 3.6 ± 2.0 † −23.3 ± 52.7 7 8 71.6 ± 17.0 58.1 ± 14.5 ∗ −17.7 ± 16.8 50.6 ± 13.4 36.2 ± 10.5 ∗ −24.4 ± 32.1 3.4 ± 1.9 2.5 ± 1.7 −16.9 ± 58.5 14 4 64.4 ± 20.6 58.3 ± 31.2 −10.3 ± 30.7 43.7 ± 8.9 30.6 ± 8.7 † −30.6 ± 5.1 6.6 ± 3.1 2.5 ± 2.1 † −66.2 ± 15.7</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/5_1s20S1076633208005394.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/5_1s20S1076633208005394.jpg" alt="Figure 6, Plots of percentage change of blood flow in untreated tumor (a) and the peripheral rim of ablated tumor (b) induced by hydralazine to baseline blood flow of 24 tested tumors. SD, standard deviation." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/6_1s20S1076633208005394.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/6_1s20S1076633208005394.jpg" alt="Figure 7, Maximum-intensity projection (MIP) and blood flow images before and after hydralazine injection on days 2, 7, and 14 show that hydralazine decreased the blood flow in both untreated viable tumor (left) and the peripheral rim of ablated tumor (right) . Dotted lines mark the region of untreated viable tumor (left) and peripheral rim of ablated tumor (right). L, left; RF, radiofrequency." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="roc-analysis"><span class="mr-2">ROC Analysis</span><a href="#roc-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/7_1s20S1076633208005394.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RadiofrequencyAblation/7_1s20S1076633208005394.jpg" alt="Figure 8, Receiver-operating characteristic curves of the percentage change of blood flow in response to phenylephrine (solid line) and hydralazine (dashed line) on days 2 (a) , 7 (b) , and 14 (c) ." class="lazyload" data-proofer-ignore></a></p><p>Table 3</p><p>AUCs and 95% CIs of the Receiver-operating Characteristic Curves of Percentage Changes of Blood Flow in Response to Phenylephrine and Hydralazine</p><p>Phenylephrine Hydralazine AUC 95% CI AUC 95% CI Day 2 0.82 0.64–1.00 0.58 0.33–0.82 Day 7 0.81 0.56–1.00 0.66 0.37–0.95 Day 14 0.81 0.46–1.00 0.75 0.26–1.00 Pooled data 0.83 0.71–0.95 0.63 0.46–0.80</p><p>AUC, area under the curve; CI, confidence interval.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusion-1"><span class="mr-2">Conclusion</span><a href="#conclusion-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Hong K., Georgiades C.S., Geschwind J.F.: Technology insight: Image-guided therapies for hepatocellular carcinoma—intra-arterial and ablative techniques. Nat Clin Pract Oncol 2006; 3: pp. 315-324.</p><li><p>2. Gazelle G.S., McMahon P.M., Beinfeld M.T., Halpern E.F., Weinstein M.C.: Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiology 2004; 233: pp. 729-739.</p><li><p>3. Harrison L.E., Koneru B., Baramipour P., et. al.: Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003; 197: pp. 759-764.</p><li><p>4. Curley S.A.: Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Ann Surg Oncol 2008; 15: pp. 11-13.</p><li><p>5. Lim H.K., Choi D., Lee W.J., et. al.: Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001; 221: pp. 447-454.</p><li><p>6. Lu D.S., Yu N.C., Raman S.S., et. al.: Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234: pp. 954-960.</p><li><p>7. Lencioni R., Cioni D., Bartolozzi C.: Percutaneous radiofrequency thermal ablation of liver malignancies: techniques, indications, imaging findings, and clinical results. Abdom Imaging 2001; 26: pp. 345-360.</p><li><p>8. Veit P., Antoch G., Stergar H., Bockisch A., Forsting M., Kuehl H.: Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 2006; 16: pp. 80-87.</p><li><p>9. Okuma T., Okamura T., Matsuoka T., et. al.: Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results. Ann Nucl Med 2006; 20: pp. 115-121.</p><li><p>10. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M.: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002; 160: pp. 985-1000.</p><li><p>11. Baluk P., Morikawa S., Haskell A., Mancuso M., McDonald D.M.: Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003; 163: pp. 1801-1815.</p><li><p>12. Ekelund L.: Pharmacoangiography of the kidney: an overview. Urol Radiol 1980; 2: pp. 9-15.</p><li><p>13. Miles K.A., Griffiths M.R., Perfusion C.T.: a worthwhile enhancement?. Br J Radiol 2003; 76: pp. 220-231.</p><li><p>14. Zima A., Carlos R., Gandhi D., Case I., Teknos T., Mukherji S.K.: Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy?. AJNR Am J Neuroradiol 2007; 28: pp. 328-334.</p><li><p>15. Cuenod C.A., Leconte I., Siauve N., et. al.: Deconvolution technique for measuring tissue perfusion by dynamic CT: application to normal and metastatic liver. Acad Radiol 2002; 9: pp. S205-S211.</p><li><p>16. Krupka T.M., Weinberg B.D., Wu H., Ziats N.P., Exner A.A.: Effect of intratumoral injection of carboplatin combined with pluronic P85 or L61 on experimental colorectal carcinoma in rats. Exp Biol Med (Maywood) 2007; 232: pp. 950-957.</p><li><p>17. Tozer G.M., Maxwell R.J., Griffiths J.R., Pham P.: Modification of the 31P magnetic resonance spectra of a rat tumour using vasodilators and its relationship to hypotension. Br J Cancer 1990; 62: pp. 553-560.</p><li><p>18. Ohyama N., Yamaguchi S.: Effects of phenylephrine and prazosin on axial movement of the rat incisor and arterial blood pressure. Jpn J Pharmacol 1999; 80: pp. 271-274.</p><li><p>19. Goldberg S.N., Gazelle G.S., Compton C.C., Mueller P.R., Tanabe K.K.: Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000; 88: pp. 2452-2463.</p><li><p>20. Hsu C.P., Razavi M.K., So S.K., Parachikov I.H., Benaron D.A.: Liver tumor gross margin identification and ablation monitoring during liver radiofrequency treatment. J Vasc Interv Radiol 2005; 16: pp. 1473-1478.</p><li><p>21. Dromain C., de Baere T., Elias D., et. al.: Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 2002; 223: pp. 255-262.</p><li><p>22. Chaplin D.J., Acker B.D., Horsman M.R.: Reduction of tumour blood flow by vasoactive drugs: a role in cancer therapy. Biomed Biochim Acta 1989; 48: pp. S264-S268.</p><li><p>23. Chan R.C., Babbs C.F., Vetter R.J., Lamar C.H.: Abnormal response of tumor vasculature to vasoactive drugs. J Natl Cancer Inst 1984; 72: pp. 145-150.</p><li><p>24. Bradley J.G.: Nonprescription drugs and hypertension. Which ones affect blood pressure?. Postgrad Med 1991; 89: pp. 195-197.</p><li><p>25. Arce C., Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Candelaria M., Duennas-Gonzalez A.: Hydralazine target: from blood vessels to the epigenome. J Transl Med 2006; 4: pp. 10.</p><li><p>26. Nielsen F.U., Topp S., Horsman M.R., Overgaard J., Stodkilde-Jorgensen H., Maxwell R.J.: Localized in vivo 1H NMR spectroscopy of murine tumours: effect of blood flow reduction. NMR Biomed 1999; 12: pp. 175-183.</p><li><p>27. Phongkitkarun S., Kobayashi S., Kan Z., Lee T.Y., Charnsangavej C.: Quantification of angiogenesis by functional computed tomography in a Matrigel model in rats. Acad Radiol 2004; 11: pp. 573-582.</p><li><p>28. Lassau N., Chami L., Benatsou B., Peronneau P., Roche A.: Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 2007; 17: pp. F89-F98.</p><li><p>29. Bisdas S., Medov L., Baghi M., et. al.: A comparison of tumour perfusion assessed by deconvolution-based analysis of dynamic contrast-enhanced CT and MR imaging in patients with squamous cell carcinoma of the upper aerodigestive tract. Eur Radiol 2008; 18: pp. 843-850.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-16/'>Volume 16</a>, <a href='/categories/issue-3/'>Issue 3</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Radiofrequency%20Ablation%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fradiofrequency-ablation%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Radiofrequency%20Ablation%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fradiofrequency-ablation%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fradiofrequency-ablation%2F&text=Radiofrequency%20Ablation%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/3d-ct-volumetry-of-the-lung-using-multidetector-row-ct/"><div class="card-body"> <em class="small" data-ts="1235840400" data-df="ll" > Feb 28, 2009 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>3D-CT Volumetry of the Lung Using Multidetector Row CT</h3><div class="text-muted small"><p> Rationale and Objectives The aim of this study was to evaluate the accuracy of measurements of lung volumes reconstructed using three-dimensional computed tomographic (CT) imaging from thin-sectio...</p></div></div></a></div><div class="card"> <a href="/posts/a-few-words-about-lobbying/"><div class="card-body"> <em class="small" data-ts="1235840400" data-df="ll" > Feb 28, 2009 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>A few words about lobbying</h3><div class="text-muted small"><p> During the 2008 presidential campaign, both the winner and the loser spent a considerable amount of rhetoric denouncing the activities of lobbyists, scorning (but not always spurning) donations fro...</p></div></div></a></div><div class="card"> <a href="/posts/abstracts-of-funded-national-institutes-of-health-grants/"><div class="card-body"> <em class="small" data-ts="1235840400" data-df="ll" > Feb 28, 2009 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Abstracts of Funded National Institutes of Health Grants</h3><div class="text-muted small"><p> A novel device to allow zoom-in imaging for PET scanners Grant Number:5R33CA110011-04PI Name:Tai, Yuan-Chuan Abstract: Description (provided by applicant): Positron emission tomography (PET) has ...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/quantitative-estimation-of-dynamic-contrast-enhanced-mri-parameters-in-rat-brain-gliomas-using-a-dua/" class="btn btn-outline-primary" prompt="Older"><p>Quantitative Estimation of Dynamic Contrast Enhanced MRI Parameters in Rat Brain Gliomas Using a Dual Surface Coil System</p></a> <a href="/posts/reproducibility-of-breast-arterial-calcium-mass-quantification-using-digital-mammography/" class="btn btn-outline-primary" prompt="Newer"><p>Reproducibility of Breast Arterial Calcium Mass Quantification Using Digital Mammography</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
